Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with…

Cross-sectionalFrontiers in medicine· 2026

Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.

Soumaya Mrabet, Ghada Saad, Asma Ben Cheikh … Elhem Ben Jazia

GastroenterologyCross-sectionalDiagnosisQ1IF 3.4

Metabolic dysfunction-associated steatotic liver disease affected most patients with type 2 diabetes.

Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.

Soumaya Mrabet … Elhem Ben Jazia

Frontiers in medicine · 2026 · Q1 in General Medicine

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (non-alcoholic fatty liver disease), is today the leading cause of chronic liver conditions in the context of a global epidemic of obesity and metabolic disorders.

Purpose

Our study aims to determine the prevalence of MASLD and advanced liver fibrosis as well as the associated factors in patients with type 2 diabetes Mellitus (T2D).

Methods

Cross-sectional study including 149 patients with T2D, conducted in the Endocrinology-Diabetology and Hepato-Gastroenterology departments over a period of 6 months.

n = 149 patients

Results

most people with type 2 diabetes also had fatty liver disease

AOR by subgroup · 95% CI

More results

The average age of the patients was 57.9 ± 11.8 years, with a female predominance (63.8%).

The median liver stiffness measurement was 5.0 kPa (IQR 4.0-6.5).

More results

Advanced fibrosis could not be ruled out (≥8 kPa) in 17.4% [95% CI (11.7-24.5), n = 26], which included 13.4% ( n = 20) in the intermediate-risk zone (8-11.99 kPa) and 4% ( n = 6) at high risk of advanced fibrosis (≥12 kPa).

“

Conclusion · 1 of 2

In our study, we found that 69.1% of participants met the criteria for MASLD, and advanced fibrosis could not be ruled out in 17.4% of patients, with 4% being at high risk (≥12 kPa).

Conclusion · 2 of 2

It is essential to identify these at-risk patients who require multidisciplinary management in order to prevent progression to cirrhosis and its complications.

Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.

Determinants of metabolic dysfunction associated steatotic liver disease and liver fibrosis in patients with type 2 diabetes mellitus: a cross-sectional study.

Related papers